<DOC>
	<DOCNO>NCT00129818</DOCNO>
	<brief_summary>The study design assess efficacy safety famciclovir 250 mg twice day ( bid ) suppressive treatment men woman herpes virus type 2 ( HSV-2 ) infection , without report history genital herpes without herpes virus type 1 ( HSV-1 ) seropositivity .</brief_summary>
	<brief_title>A Study Evaluate Effect Famciclovir Reducing Herpes Virus Shedding</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Males nonpregnant female least 18 year age HSV2 seropositive serology without history clinically diagnose recurrent genital herpes Pregnancy History renal dysfunction Use immunosuppressive therapy , include steroid ( topical inhale ) , use probenecid Hypersensitivity famciclovir , valacyclovir drug similar chemical structure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Genital herpes</keyword>
	<keyword>viral shed</keyword>
	<keyword>famciclovir</keyword>
	<keyword>Symptomatic genital herpes</keyword>
	<keyword>Asymptomatic genital herpes</keyword>
</DOC>